Recent PIRS Stock Price | PIRS Stock Predictions | |
$11.71 | +4682.24% |
$560.00 |
Recent PIRS Analyst Ratings Breakdown, Making PIRS Stock Predictions | ||||
---|---|---|---|---|
Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
Strong buy ratings: | 1 | 1 | 1 | 1 |
Buy ratings: | 0 | 0 | 0 | 0 |
Hold ratings: | 0 | 1 | 1 | 1 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 1.0 | 2.0 | 2.0 | 2.0 |
For the PIRS stock predictions from the analysts covering Pieris Pharmaceuticals Inc, we have collected all of the individual PIRS stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 1 different analysts covering PIRS (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since PIRS stock predictions may vary widely, another useful metric to consider is the median PIRS stock prediction, which represents the price at which half of the analysts
made PIRS stock predictions that were higher and half made PIRS stock predictions that were lower. This makes for a different take on the PIRS stock predictions out there, as compared to average or mean.
And that median across all the individual PIRS stock predictions was: $560.0 as of 2024-04-30.
The very highest of the PIRS stock predictions for one year price target was $560.0, while the very lowest of the PIRS stock predictions in the analyst group was
$560.0 (with a standard deviation of $0.0). Get the latest Zacks research report on PIRS — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
NVST Stock Predictions
CRL Stock Predictions
TGS Stock Predictions
MDRX Stock Predictions
BBDC Stock Predictions
OTIS Stock Predictions
NTB Stock Predictions
AGX Stock Predictions
AGRO Stock Predictions
|
|
Strong Buy (4.00 out of 4) 84th percentile
(ranked higher than approx. 84% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |